<?xml version="1.0" encoding="UTF-8"?>
<FundingAwardNotice xmlns="urn:xmlns:nl:pop-project:cerif-profile-1.0-EXPERIMENTAL"
                    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
                    xsi:schemaLocation="urn:xmlns:nl:pop-project:cerif-profile-1.0-EXPERIMENTAL ../schemas/p-o-p-profile-schema.xsd">
   <!-- A fictitious project funding award notice based on a real-world project, see http://www.narcis.nl/research/RecordID/OND1360000 -->
   <Project id="d25986"><!-- RU-secretariat -->
      <Title xml:lang="en">GlycoFlux: Novel pathways from diagnosis to galactose therapy and energy</Title>
      <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#narcis">OND1360000</Identifier>
      <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#source-url">http://www.narcis.nl/research/RecordID/OND1360000</Identifier>
      <StartDate>2016-01-01</StartDate>
      <EndDate>2019-12-31</EndDate>
      <Funders>
         <Funder>
            <OrgUnit id="d4929">
               <Acronym>NWO-CW</Acronym>
               <Name xml:lang="en">NWO Council for Chemical Sciences</Name>
               <Name xml:lang="nl">NWO Chemische Wetenschappen</Name>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#narcis">ORG1234998</Identifier>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#source-url">http://www.narcis.nl/organisation/RecordID/ORG1234998</Identifier>
               <PartOf>
                  <OrgUnit id="d5">
                     <Acronym>NWO</Acronym>
                     <Name xml:lang="en">Netherlands Organisation for Scientific Research</Name>
                     <Name xml:lang="nl">Nederlandse Organisatie voor Wetenschappelijk Onderzoek</Name>
                     <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#FundRefId">http://dx.doi.org/10.13039/501100003246</Identifier>
                     <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#narcis">ORG1236737</Identifier>
                     <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#source-url">http://www.narcis.nl/organisation/RecordID/ORG1236737</Identifier>
                  </OrgUnit>
               </PartOf>
            </OrgUnit>
         </Funder>
      </Funders>
      <Consortium>
         <Secretariat>
            <OrgUnit id="d144">
               <Acronym>Radboudumc</Acronym>
               <Name xml:lang="en">Radboud University Medical Center</Name>
               <Name xml:lang="nl">Radboud Universitair Medisch Centrum</Name>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#narcis">ORG1238551</Identifier>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#source-url">http://www.narcis.nl/organisation/RecordID/ORG1238551</Identifier>
               <PartOf>
                  <OrgUnit id="d11">
                     <Acronym>RU</Acronym>
                     <Name xml:lang="en">Radboud University Nijmegen</Name>
                     <Name xml:lang="nl">Radboud Universiteit Nijmegen</Name>
                     <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#narcis">ORG1236841</Identifier>
                     <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#source-url">http://www.narcis.nl/organisation/RecordID/ORG1236841</Identifier>
                  </OrgUnit>
               </PartOf>
            </OrgUnit>
         </Secretariat>
      </Consortium>
      <Team>
         <PrincipalInvestigator>
            <DisplayName>Dr. M. (Monique) van Scherpenzeel</DisplayName>
            <Person id="d13779">
               <PersonName>
                  <FamilyNames>Scherpenzeel</FamilyNames>
                  <FirstNames>M. (Monique)</FirstNames>
                  <OtherNames>van</OtherNames>
               </PersonName>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#narcis">PRS1310230</Identifier>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#source-url">http://www.narcis.nl/person/RecordID/PRS1310230</Identifier>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#isni">0000 0003 9205 9319</Identifier>
               <Identifier type="urn:xmlns:nl:pop-project:vocab:IdentifierTypes#dai">info:eu-repo/dai/nl/304835390</Identifier>
            </Person>
            <Affiliation>
               <OrgUnit id="d144"/>
            </Affiliation>
         </PrincipalInvestigator>
      </Team>
      <Abstract xml:lang="en">Genes underlying inherited disorders are increasingly identified by Next Generation Sequencing (NGS) techniques. However, in most cases, NGS does not result in a definite diagnosis. Synergy with a fast functional read-out largely increases the percentage of solved cases, as evidenced by my recently developed high-resolution glycoprofiling method of blood proteins. I could identify highly specific diagnostic profiles for already several genetic disorders in patients with myopathy and intellectual disability (recent papers in NEJM and Brain), highlighting the innovative nature of my approach. Based on the structural information from the specific diagnostic glycoprofile of phosphoglucomutase (PGM1) deficiency (NEJM), we successfully developed a galactose supplementation therapy. The therapy normalizes protein glycosylation, improves clinical symptoms and increases patient's energy levels. However, there is a paradox surrounding the potency of galactose supplementation in PGM1 patients: galactose is lethal for PGM1 knock-out yeast5, highly toxic for patients with other enzyme deficiencies in galactose metabolism, and induces aging in mice6-8. Preliminary data obtained at my ETH fellowship suggest that there are missing links between galactose metabolism, glycolysis and protein glycosylation. I aim to unravel novel important pathways in protein glycosylation via the 2 Key objectives of my project GlycoFlux: 1) Identification of missing links in galactose metabolism, which is extremely important for understanding pathogenic mechanisms of galactose related diseases. 2) Discovery of novel characteristic glycoprofiles by implementing glycoprofiling more widely. The profiles will provide a fast functional read-out for unsolved genetic disorders, possibly therapeutic options and directly gain insight into novel links between genes and glycosylation. My experience in glycosylation analysis and carbohydrate (bio)chemistry, combined with the access to patient samples, makes me uniquely qualified for this translational research. GlycoFlux will provide development and monitoring of therapy through understanding of poorly described metabolic pathways, fitting perfectly into the current developments towards personalized treatment.</Abstract>
   </Project>
</FundingAwardNotice>
